On July 20, 2023, Eliem Therapeutics announced plans to explore strategic alternatives to maximize shareholder value, with potential options including an acquisition, merger, or other business combination. The company also reported unaudited cash, cash equivalents, and marketable securities of approximately $102.6 million as of June 30, 2023, and revealed that it has halted development of its Kv7 program.